Every Form 4 that Milestone Pharmaceuticals (MIST) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow MIST and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MIST filings page.
Milestone Pharmaceuticals Inc. director Lisa M. Giles received a grant of stock options covering 77,000 shares of common stock. The options have an exercise price of $1.2200 per share and expire on June 10, 2036. They vest in twelve equal monthly installments starting July 10, 2026, or will be fully vested by the next annual stockholder meeting if she continues providing service.
Milestone Pharmaceuticals director Seth H. Z. Fischer received a grant of stock options covering 77,000 shares of common stock. The options have an exercise price of $1.22 per share and expire on June 10, 2036. They vest in twelve equal monthly installments starting July 10, 2026, or will be fully vested by the next annual stockholder meeting if he continues serving.
Milestone Pharmaceuticals Inc. director Duty Stuart received a grant of stock options covering 77,000 shares of common stock. The options have an exercise price of $1.22 per share and expire on June 10, 2036. Following this grant, Stuart holds options on 77,000 shares.
The award vests in twelve equal monthly installments starting on July 10, 2026, and will in any case be fully vested on the date of the next annual stockholders’ meeting, as long as Stuart continues providing service through each vesting date.
Milestone Pharmaceuticals director Robert James Wills reported a grant of stock options for 77,000 shares of Common Stock. The options have an exercise price of $1.22 per share and expire on June 10, 2036. This is a compensation-related award, not an open-market purchase.
The option vests in twelve equal monthly installments beginning on July 10, 2026, and will in any case be fully vested on the date of the next annual meeting of stockholders, as long as Wills continues providing service through each vesting date. Following this grant, he holds 77,000 option-based rights directly.
Milestone Pharmaceuticals Inc. director Michael John Tomsicek received a grant of stock options covering 77,000 shares of common stock at an exercise price of $1.22 per share. The options vest in twelve equal monthly installments beginning on July 10, 2026, and will in any case be fully vested by the date of the next annual stockholders’ meeting, as long as he continues to provide service. Following this grant, he holds 77,000 stock options directly, which are scheduled to expire on June 10, 2036.
Milestone Pharmaceuticals Inc. director Andrew Saik received a grant of stock options as part of his compensation. The award covers 77,000 options to buy common stock at an exercise price of $1.22 per share.
The options vest in twelve equal monthly installments starting on July 10, 2026, and will in any case be fully vested by the date of the company’s next annual stockholder meeting, as long as Saik continues to provide service through each vesting date. Following this grant, he holds 77,000 options directly.
Milestone Pharmaceuticals Inc. director Joseph C. Papa received a grant of stock options covering 77,000 shares of common stock. The options have an exercise price of $1.22 per share and expire on June 10, 2036. They vest in twelve equal monthly installments beginning on July 10, 2026, or will in any case be fully vested by the date of the next annual meeting of stockholders, as long as he continues providing service. Following this grant, he holds 77,000 options directly.
Milestone Pharmaceuticals President and CEO Joseph Oliveto sold 36,500 common shares of the company in an open-market transaction on April 16, 2026 at a weighted average price of $2.26 per share. The shares were sold in multiple trades between $2.25 and $2.28 per share.
The sale was made pursuant to a Rule 10b5-1 trading plan previously adopted by Oliveto, meaning the trades were pre-scheduled rather than discretionary. Following this transaction, he continues to hold 446,244 common shares directly.
Milestone Pharmaceuticals President and CEO Joseph Oliveto filed an amended insider report updating the terms of a previously disclosed stock option grant. The filing shows an employee stock option to purchase 679,000 common shares at an exercise price of $1.96 per share.
The amendment states that the exercise price on the initial filings was incorrectly stated and is now corrected. One-fourth of the option shares will vest on February 2, 2027, with one thirty-sixth of the remaining shares vesting each month afterward, as long as Oliveto continues to provide service.
Milestone Pharmaceuticals Inc. reported an amended insider transaction for its Chief Medical Officer. The officer received an employee stock option to buy 204,000 common shares at an exercise price of $1.96 per share, granted on February 2, 2026 and expiring on February 2, 2036.
The amendment corrects an initially misstated exercise price. One-fourth of the option shares vest on February 2, 2027, with one thirty-sixth of the remaining shares vesting monthly thereafter, as long as the officer continues providing services.
Milestone Pharmaceuticals Inc. reported an amended insider transaction for its Chief Operating Officer. The filing corrects the exercise price on previously reported employee stock options and confirms a grant of 204,000 options with an exercise price of $1.96 per common share.
The options expire on February 2, 2036. One-fourth of the shares underlying the option vest on February 2, 2027, and the remaining shares vest in equal monthly installments over the following 36 months, as long as the executive continues providing service through each vesting date.
Milestone Pharmaceuticals Inc. reported an amended insider transaction for its Chief Commercial Officer. On February 2, 2026, the officer received an employee stock option to purchase 204,000 common shares at an exercise price of $1.96 per share, correcting an exercise price that had been stated incorrectly in initial filings.
According to the vesting schedule, one-fourth of the option shares vest on February 2, 2027, with one thirty-sixth of the remaining shares vesting monthly thereafter, as long as the officer continues providing service. Following this grant, the officer beneficially owns 204,000 stock options, held directly.
Milestone Pharmaceuticals Inc. insider filing: the company’s CFO and EVP of Corporate Development reported an amended employee stock option grant. The filing corrects the exercise price for an option to buy 204,000 common shares at $1.96 per share, granted on February 2, 2026 and expiring on February 2, 2036. One-fourth of the option vests on February 2, 2027, with the remaining shares vesting in equal monthly installments over the following 36 months while the executive continues providing service.
Milestone Pharmaceuticals granted its Chief Commercial Officer, Lorenz Muller, new equity awards. On February 2, 2026, he received an employee stock option for 204,000 common shares at an exercise price of $1.97 per share. One-fourth of these option shares vest on February 2, 2027, and the remaining shares vest in equal monthly installments over the following thirty-six months, as long as he continues providing service.
He was also granted 136,000 restricted stock units on the same date, each representing the right to receive one common share. These RSUs vest in four equal installments on February 2 of each year from 2027 through 2030, again contingent on continued service. After these grants, he beneficially owns all 204,000 option awards and 136,000 RSUs directly.
Milestone Pharmaceuticals Inc. granted new equity awards to its CFO and EVP of Corporate Development, Amit Hasija. On February 2, 2026, he received an employee stock option covering 204,000 common shares at an exercise price of $1.97 per share, expiring on February 2, 2036. One-fourth of these option shares vest on February 2, 2027, with the remaining shares vesting monthly over the following 36 months, contingent on continued service. He also received 136,000 restricted stock units, each representing one common share. These RSUs vest in four equal annual installments on February 2 of 2027, 2028, 2029, and 2030, also subject to continued service.
Milestone Pharmaceuticals Inc. reported that its Chief Operating Officer, Jeffrey Edward Nelson, received new equity awards. On February 2, 2026, he was granted an option to buy 204,000 common shares at $1.97 per share and 136,000 restricted stock units.
One-fourth of the option vests on February 2, 2027, with the remaining shares vesting monthly over three years, contingent on continued service. The RSUs vest in four equal annual installments on February 2 of 2027, 2028, 2029, and 2030, also subject to continued service.
Milestone Pharmaceuticals Inc. reported new equity awards to Chief Medical Officer David Bharucha. On February 2, 2026, he received an employee stock option covering 204,000 common shares at an exercise price of $1.97 per share, expiring February 2, 2036.
One-fourth of the option vests on February 2, 2027, with the remaining shares vesting in equal monthly installments over the following 36 months, assuming continued service. He also received 136,000 restricted stock units, each representing one common share, vesting in four equal annual installments on February 2 of 2027, 2028, 2029 and 2030, subject to continued service.
Milestone Pharmaceuticals Inc. President and CEO Joseph Oliveto reported new equity awards. On February 2, 2026, he was granted an employee stock option for 679,000 common shares at an exercise price of $1.97 per share and a restricted stock unit award covering 453,000 common shares.
Both awards are held directly and vest over several years. The option vests 25% on February 2, 2027, with the remaining option shares vesting monthly over the following 36 months. The restricted stock units vest in four equal annual installments from February 2, 2027 through February 2, 2030, contingent on continued service.
Milestone Pharmaceuticals Chief Medical Officer David Bharucha reported new equity awards and related share sales. On December 12, 2025, he acquired 100,000 performance stock units (PSUs) that vested when the FDA granted a New Drug Application approval letter for Cardamyst (etripamil), and he also received an option for 100,000 common shares at an exercise price of $1.74, vesting in two equal installments in 2026. On December 15, 2025, he sold 58,007 common shares at a weighted average price of $2.32 under a sell-to-cover arrangement for taxes. On January 26, 2026, 20,100 restricted stock units were converted into common shares, followed by the sale of 12,245 shares at a weighted average price of $1.93, also to cover tax liabilities. After these transactions, he directly owned 113,181 common shares and 60,300 restricted stock units, with remaining RSUs vesting in annual installments through 2029.
Milestone Pharmaceuticals Inc. Chief Operating Officer Nelson Jeffrey Edward reported multiple equity award events tied to Cardamyst (etripamil). A 100,000-share performance stock unit award vested after FDA New Drug Application approval of Cardamyst, with each PSU delivering one common share. He also received an option for 100,000 common shares at $1.74 per share, vesting in two equal installments on June 12, 2026 and December 12, 2026, subject to continued service. On January 26, 2026, 20,100 restricted stock units converted into common shares, and 12,245 shares were sold at a weighted average price of $1.93 under a sell-to-cover arrangement to satisfy tax liabilities, following an earlier 58,007-share sell-to-cover sale at $2.32 on December 15, 2025.
Milestone Pharmaceuticals Chief Commercial Officer Muller Lorenz reported multiple equity compensation events tied to regulatory and service milestones. On December 12, 2025, a performance stock unit award for 100,000 common shares vested after the U.S. Food and Drug Administration issued a New Drug Application Approval Letter for Cardamyst (etripamil), and a separate employee stock option for 100,000 shares with a $1.74 exercise price was granted, vesting in two halves on June 12, 2026 and December 12, 2026.
On January 26, 2026, 20,100 restricted stock units converted into common shares as part of an award that vests in four annual installments through January 26, 2029. Shares totaling 53,566 at a weighted average price of $2.32 and 11,180 at $1.93 were sold solely to cover tax liabilities from PSU and RSU vesting. After these transactions, Lorenz directly owned 205,406 common shares, 100,000 stock options, and 60,300 restricted stock units.
Milestone Pharmaceuticals CFO & EVP of Corp. Development Amit Hasija reported multiple equity transactions. On December 12, 2025, he acquired 100,000 common shares from a performance stock unit award that vested when the FDA issued a New Drug Application approval letter for Cardamyst (etripamil), and received an option for 100,000 shares at an exercise price of $1.74.
On December 15, 2025, he sold 58,007 common shares at a weighted average price of $2.32 under a sell-to-cover arrangement for tax liabilities. On January 26, 2026, 20,100 restricted stock units converted into common shares and 12,245 of those shares were sold at a weighted average price of $1.93, also to cover taxes. After these transactions, he directly held 99,848 common shares, 100,000 stock options, and 60,300 restricted stock units.
Milestone Pharmaceuticals President and CEO Joseph Oliveto reported equity awards tied to FDA approval and routine tax-related sales. On December 12, 2025, he acquired 280,000 performance stock units and a matching 280,000-share stock option at $1.74, vesting in two equal tranches in 2026 after Cardamyst (etripamil) received a New Drug Application approval letter.
He also reported sell-to-cover sales of 133,054 common shares at $2.32 on December 15, 2025 and 34,523 shares at $1.93 on January 26, 2026, executed solely to cover income tax liabilities upon PSU and RSU vesting. On January 26, 2026, 66,600 RSUs converted into common shares as part of a four-year vesting schedule, leaving him with 482,744 common shares and 199,800 RSUs directly beneficially owned.
Milestone Pharmaceuticals President and CEO Joseph Oliveto reported pre‑planned stock sales under a Rule 10b5-1 trading plan. On January 7, 2026, he sold 500 common shares at $2.25 per share, and on January 8, 2026, he sold an additional 43,000 common shares at $2.25 per share. After these transactions, he directly beneficially owned 303,721 common shares.
The filing notes that the trading plan was adopted on September 30, 2025, which means the sales were scheduled in advance. The reported per-share price on January 8 is a weighted average; the shares were sold in multiple trades at prices ranging from $2.25 to $2.265.
Milestone Pharmaceuticals Inc.'s chief commercial officer reported an insider transaction involving the company's common shares.
On 12/09/2025, the officer disposed of 25,000 common shares in a transaction coded "G", which the filing explains is a bona fide gift made for no consideration to members of the reporting person's family who live outside the reporting person's household.
Following this gift, the reporting person directly beneficially owns 150,052 common shares of Milestone Pharmaceuticals.